Axa’s Corcept Therapeutics CORT Stock Holding History

Axa’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,990	Closed	-$570K	–	1134
2025 Q1	$570K	Sell	4,990 -24,850	-83%	-$1.51M	﹤0.01%	914
2024 Q4	$1.5M	Buy	29,840 +20,023	+204%	+$1.05M	﹤0.01%	811
2024 Q3	$454K	Sell	9,817 -3,131	-24%	-$111K	﹤0.01%	974
2024 Q2	$421K	Sell	12,948 -9,674	-43%	-$265K	﹤0.01%	968
2024 Q1	$570K	Buy	+22,622	New	+$534K	﹤0.01%	919
2023 Q1	–	Sell	-61,700	Closed	-$1.25M	–	1121
2022 Q4	$1.25M	Buy	61,700 +36,000	+140%	+$902K	﹤0.01%	846
2022 Q3	$659K	Sell	25,700 -38,875	-60%	-$1.04M	﹤0.01%	923
2022 Q2	$1.54M	Buy	64,575 +34,875	+117%	+$760K	0.01%	812
2022 Q1	$669K	Buy	+29,700	New	+$632K	﹤0.01%	1003
2021 Q3	–	Sell	-13,300	Closed	-$293K	–	1242
2021 Q2	$293K	Hold	13,300	–	–	﹤0.01%	1173
2021 Q1	$316K	Hold	13,300	–	–	﹤0.01%	1131
2020 Q4	$348K	Hold	13,300	–	–	﹤0.01%	1117
2020 Q3	$231K	Hold	13,300	–	–	﹤0.01%	1138
2020 Q2	$224K	Hold	13,300	–	–	﹤0.01%	1164
2020 Q1	$158K	Hold	13,300	–	–	﹤0.01%	1118
2019 Q4	$161K	Hold	13,300	–	–	﹤0.01%	1141
2019 Q3	$188K	Hold	13,300	–	–	﹤0.01%	1252
2019 Q2	$148K	Hold	13,300	–	–	﹤0.01%	1244
2019 Q1	$156K	Hold	13,300	–	–	﹤0.01%	1276
2018 Q4	$178K	Hold	13,300	–	–	﹤0.01%	1246
2018 Q3	$186K	Sell	13,300 -3,500	-21%	-$48.9K	﹤0.01%	1299
2018 Q2	$264K	Sell	16,800 -3,800	-18%	-$66.1K	﹤0.01%	1259
2018 Q1	$339K	Buy	+20,600	New	+$382K	﹤0.01%	1234

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Axa's CORT Position: Q2 2025 in Review

Axa sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 4,990 shares — an estimated $570K sold.

Axa first reported a position in CORT in Q1 2018 and held it in 23 quarters. The position peaked at $1.54M in Q2 2022. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

Axa reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
Axa sold 4,990 Corcept Therapeutics shares in Q2 2025, an estimated $570K.
Axa first reported a position in Corcept Therapeutics in Q1 2018 and held it in 23 quarters.
Axa's Corcept Therapeutics position peaked at $1.54M in Q2 2022.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Axa's 13F filing for Q2 2025, filed 14 Aug 2025.